TRIAL DETAIL

Phase I (PH I) Mad Refractory Solid Tumor Study

Drug:
Trial Name:
Phase I (PH I) Mad Refractory Solid Tumor Study
NCT#:
Conditions:
Neoplasms
Status:
Completed
Phase:
1
Start Date 07/01/2004
Age of Trial (yrs) 19.8
Treatment Phase:
Gleevec-resistant
Drug Category:
KIT/PDGFRA inhibitor + SRC inhibitor
Strategy:
Block KIT + Block KIT Signal Path
Trial Type:
GIST not specified. GIST patients known to be enrolled.
Other Protocol IDs:
CA180-003
Sponsor:
Bristol Myers-Squibb
Patient Contact:
Contact email:
Contact Phone:
Randomized:
IV or Oral:
Oral
Trial Notes:

Trial Links

Trial Results
 
 

Drug Information
Dasatinib inhibits KIT D816V mutation-an imatinib-resistant activating mutation
 
Sprycel.com
 
Sprycel reimbursement support (Destination Access)
 
Sprycel prescribing information (PDF)
 
Dasatinib inhibits PDGFRA D842V mutation - Debiec-Rychter - 2008
 
Dasatinib inhibits activity of wild-type, juxtamembrane and activation loop mutant KIT (Heinrich, et al)
 
FDA drug information page (technical information about the drug approval, etc)
 
Effect of a proton pump inhibitor on the pharmacokinetics of imatinib (mentions that dasatinib levels are highly affected by PPIs).
 
The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib
 
FDA: Increased Pulmonary Arterial Hypertension Risk Seen With Dasatinib
 
FDA website: Sprycel (dasatinib): Drug Safety Communication - Risk of Pulmonary Arterial Hypertension
 
Severe adverse events associated with the use of second-line BCR/ABL tyrosine kinase inhibitors: preferential occurrence in patients with comorbidities
 
Disintegration of chemotherapy tablets (including dasatinib) for oral administration in patients with swallowing difficulties
 
Activity of dasatinib against L576P KIT mutant melanoma: Molecular, cellular, and clinical correlates
 

Trial Sites

Name
Address
City
State
Zip
Country
450 Brookline Ave
Boston
MA
02215-5450
USA
Garscube Estate
Glasgow
G61 1BD
UK